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Abstract Peptide-based £uoromethyl ketones have been con-
sidered for many years to be highly speci¢c caspase inhibitors
distinctly blocking the progress of apoptosis in a variety of
systems. Here we demonstrate that these compounds can sig-
ni¢cantly reduce rhinovirus multiplication in cell culture. In
their methylated forms they block eIF4GI cleavage in vivo
and in vitro and inhibit the activity of picornaviral 2A protein-
ases.
# 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Human rhinoviruses (HRVs) and enteroviruses are small,
(+)-strand RNA viruses which belong to the Picornaviridae
family. A crucial step in the life cycle of picornaviruses is the
processing of the polyprotein precursor synthesized from a
single open reading frame. HRVs and enteroviruses encode
two proteinases designated 2A and 3C which are responsible
for polyprotein processing. The ¢rst cleavage is catalyzed by
the 2A proteinase (2Apro) separating the viral capsid proteins
from the non-capsid proteins [1,2]. In terms of structure these
viral proteinases are unique as they resemble serine protein-
ases with a typical chymotrypsin-like fold but harbor Cys
rather than Ser as an active site residue [3].
Cells frequently undergo apoptosis when infected with rep-
resentatives of Picornaviridae such as poliovirus and coxsack-
ievirus (CV) [4^9]. Caspases act as central mediators in apo-
ptosis participating in both signaling and e¡ector pathways
[10,11]. They are typical cysteine proteinases cleaving the sub-
strate usually at speci¢c aspartate residues in the P1 position
[12,13]. Caspases are highly conserved throughout evolution
and are structurally unrelated to viral 2A and 3C proteinases
[14,15].
Several £uoromethyl ketone (fmk)-derivatized peptides have
been developed as inhibitors of caspases [16,17]. Fmk acts as a
trapping group which upon covalent binding to ^SH of an
adjacent cysteine residue causes irreversible inhibition. These
inhibitors are known to prevent apoptosis in various cell lines
without major cytotoxic side e¡ects [18]. In this study we
demonstrate that caspase inhibitors benzyloxycarbonyl-Val-
Ala-Asp(OMe)-£uoromethyl ketone (zVAD.fmk) and benzy-
loxycarbonyl-Ile-Glu(OMe)-Thr-Asp(OMe)-£uoromethyl ke-
tone (zIETD.fmk) inhibit HRV multiplication in HeLa cells.
These compounds also block eukaryotic initiation factor (eIF)
4GI cleavage in vivo and in vitro and signi¢cantly a¡ect the
viral 2Apro activity in vitro.
2. Materials and methods
2.1. Media, reagents, chemicals
The caspase inhibitors zVAD.fmk, unmethylated zVAD.fmk, and
zIETD.fmk were purchased from Enzyme Systems Products (Liver-
more, CA, USA) and from Calbiochem (La Jolla, CA, USA). Rabbit
anti-eIF4GI was supplied by Dr. R. Rhoads (Louisiana State Univer-
sity, Shreveport, LA, USA). TRPIITTA-para-nitroanilide (pNA) was
purchased from piChem (Graz, Austria) [19]. Human cervix carcino-
ma HeLa cells (strain Ohio, European Collection of Cell Cultures,
Salisbury, UK) were grown in Dulbecco’s modi¢ed Eagle’s medium
(DMEM) (Gibco, Eggersheim, Germany) supplemented with 10%
heat-inactivated fetal calf serum (FCS) (Gibco), 2 mM L-glutamine,
100 U/ml penicillin, and 100 Wg/ml streptomycin at 37‡C in a humidi-
¢ed atmosphere with 5% CO2.
2.2. Infection of cells with HRV2
HRV2 (American Type Culture Collection) was grown in suspen-
sion cultures of HeLa cells and puri¢ed as described previously [20].
Virus titers were determined as 50% tissue culture infectious doses
(TCID50/ml) according to Reed and Muench [21]. HeLa cells were
infected at 80^90% con£uence in minimal essential medium (MEM)
(Gibco) containing 2% FCS, 2 mM L-glutamine, 30 mM MgCl2, 100
U/ml penicillin, and 100 Wg/ml streptomycin with puri¢ed HRV2 at a
multiplicity of infection of 100 [20]. One hour post infection (p.i.) non-
incorporated virus was removed by washing three times with MEM.
Infected HeLa cell cultures were incubated for a total of 12 h and the
TCID50 was determined.
2.3. Treatment of cells with caspase inhibitors
Stock solutions of caspase inhibitors (100 mM in dimethyl sulfox-
ide, DMSO) were diluted in MEM so that the ¢nal content of DMSO
never exceeded 0.2%. 200 WM zVAD.fmk and 100 WM zIETD.fmk
were added to cells at the times indicated.
2.4. Labeling of viral proteins
HeLa cells were infected with HRV2 as above in DMEM (lacking
L-methionine and L-cysteine) in the presence of 200 WM zVAD.fmk
and 100 WM zIETD.fmk. Four hours p.i. medium was supplemented
with fresh solutions of inhibitors and 5 h p.i. [35S]methionine was
added to a ¢nal concentration of 100 WCi/ml. Twelve hours p.i. cells
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were harvested and solubilized directly in Laemmli sample bu¡er.
Samples were subjected to 12.5% sodium dodecyl sulfate^polyacryl-
amide gel electrophoresis (SDS^PAGE) and analyzed by autoradiog-
raphy.
2.5. Inhibition of eIF4GI cleavage in vivo and in vitro
For in vivo eIF4GI cleavage HeLa cells were infected with HRV2
as above in the presence of 200 WM zVAD.fmk and 100 WM
zIETD.fmk. Fresh inhibitors were added after 4 h. Eight hours p.i.
cells were solubilized in Laemmli sample bu¡er, samples were sub-
jected to 6% SDS^PAGE and analyzed by immunoblotting using a
polyclonal antibody against the N-terminus of eIF4GI. Detection of
inhibition of in vitro eIF4GI cleavage was performed by incubation of
9 Wg of HeLa cell cytoplasmic protein extracts [22] with 20 ng of
puri¢ed HRV2 2Apro in bu¡er A (100 mM NaCl, 25 mM Tris^HCl,
1 mM EDTA, 5 mM dithiothreitol, pH 8). Cleavage reaction was
carried out at 30‡C in the presence and in the absence of 15 WM
zVAD.fmk, 15 WM of unmethylated zVAD.fmk or 15 WM
zIETD.fmk. After 4 h the incubation was terminated by adding
Laemmli sample bu¡er. Samples were analyzed by 6% SDS^PAGE
and Western blotting.
2.6. In vitro analysis of the inhibition of HRV2 VP1-2Apro
self-processing activity
Plasmid preparation of pHRV2 VP1-2Apro, two-step in vitro tran-
scription and in vitro translation were employed as described [23].
After preincubation for 2 min at 30‡C and 10 min of protein syn-
thesis, inhibitors were added to a ¢nal concentration of 200 WM.
Control reactions contained DMSO (0.2% v/v) only.
2.7. Inhibition of HRV2 2Apro activity
Recombinant HRV2 2Apro was puri¢ed as described previously
[24]. Activity of the enzyme was detected in the colorimetric assay
using the HRV2 2Apro-speci¢c chromogenic peptide substrate
TRPIITTA-pNA derived from the C-terminus of VP1 of the cleavage
site in the viral polyprotein precursor [19,25]. The HRV2 2Apro activ-
ity assay was performed at 25‡C in 100 Wl of bu¡er A with 1 Wg of
2Apro and was initiated by the addition of 0.25 WM TRPIITTA-pNA.
Absorbance was continuously monitored for 20 min at V=405 nm
against a blank containing no enzyme. To test inhibitory activities 50
WM each of zVAD.fmk, unmethylated zVAD.fmk and zIETD.fmk
were added to the reaction mixture just before addition of the sub-
strate.
3. Results
3.1. Caspase inhibitors a¡ect HRV2 multiplication
The in£uence of caspase inhibitors on apoptosis induced by
poliovirus and CV has been described previously [4^9]. Sim-
ilarly apoptosis was blocked by caspase inhibitors when HeLa
cells were infected with HRVs (data not shown). To investi-
gate the e¡ect on HRV2 multiplication, HeLa cells were in-
fected in the presence and in the absence of the caspase in-
hibitors (Fig. 1A). 200 WM zVAD.fmk and 100 WM
zIETD.fmk were added at the indicated times of infection
and the total virus titers were determined 12 h p.i. It was
observed that addition of the caspase inhibitors not only re-
duced progress of apoptosis (data not shown), but also af-
fected HRV multiplication. The extent of suppression of virus
production was dependent on the time of addition of inhib-
itors. Virus titers were not changed signi¢cantly when the
caspase inhibitors were added at the time of infection. How-
ever, there was a progressive inhibition of virus multiplication
when the substances were added up to 4 h p.i. Under these
conditions virus titers were reduced by about 50-fold at 200
WM zVAD.fmk and by 25-fold at 100 WM zIETD.fmk (Fig.
1A). Addition of inhibitors at later times had only a very
moderate e¡ect. Adding inhibitors at 8 h p.i. did not cause
any signi¢cant reduction in virus titers.
In order to further investigate the inhibitory e¡ect of
zVAD.fmk and zIETD.fmk, a similar experiment was per-
formed in which caspase inhibitors were added once, twice
and three times at 4-h intervals during HRV2 infection (Fig.
1B). When inhibitors were added at the time of infection and
again at 4 h p.i., the inhibitory e¡ect on virus multiplication
was much more pronounced. Further addition of inhibitors at
8 h p.i. decreased virus titers by about 2000-fold for
zVAD.fmk and 1000-fold for zIETD.fmk as determined 12
h p.i. However, without further addition of caspase inhibitors
there was almost full recovery of virus yield after 24 h of
incubation (data not shown). Thus, inhibition of HRV multi-
plication by these caspase inhibitors is obviously a transient
phenomenon.
3.2. zVAD.fmk and zIETD.fmk inhibit HRV protein synthesis
To check whether the reduction in HRV production in
HeLa cells was caused by inhibition of viral synthesis or by
a block in viral maturation, we performed 35S-labeling experi-
ments of viral proteins in the presence and in the absence of
the caspase inhibitors. It was found that both caspase inhib-
itors blocked synthesis of HRV2 capsid proteins whereas cel-
lular protein synthesis was not a¡ected signi¢cantly (Fig. 2A).
In the presence of these inhibitors there was obviously no host
cell shut-o¡ of cellular protein synthesis.
Fig. 1. E¡ect of zVAD.fmk and zIETD.fmk on HRV2 multiplica-
tion. A: Virus titers were determined 12 h p.i. of HeLa cells in-
fected with HRV2 in the absence or in the presence of 200 WM
zVAD.fmk (gray bars) or 100 WM zIETD.fmk (black bars) added
either at the time of infection (0 h p.i.) or 2 h, 4 h, 6 h, 8 h p.i. as
indicated. For the determination of the standard deviations the ex-
periment was repeated three times under the same conditions.
B: Virus titers were determined 12 h p.i. of HeLa cells infected with
HRV2 in the absence or in the presence of 200 WM zVAD.fmk
(gray bars) or 100 WM zIETD.fmk (black bars) supplemented either
once, twice or three times during infection (at 0, 4 and 8 h p.i., re-
spectively) as indicated. For the determination of the standard devi-
ations the experiment was repeated three times under the same con-
ditions.
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3.3. Caspase inhibitors block eIF4GI processing in vivo and in
vitro
Shut-o¡ of cellular protein synthesis is caused by direct
2Apro cleavage of eIF4GI and II which leads to a stop in
the cap-dependent initiation of translation [26,27]. eIF4GI
and II act as sca¡olding proteins in the eIF4F initiation factor
complex which comprises among others the cap binding pro-
tein eIF4E, the helicase eIF4A and eIF3, which mediates
small ribosomal subunit binding [28,29]. In addition, eIF4G
also provides binding sites for poly(A) binding protein and for
mnk-1 kinase [30]. Cleavage of eIF4G by 2Apro releases the
eIF4E cap binding domain from the eIF4F complex thus pre-
venting recognition of capped mRNAs. In contrast to cellular
mRNAs, picornaviral RNAs do not contain a cap but instead
protein synthesis is initiated at an internal ribosome entry site.
Consequently, picornaviral translation is not inhibited by
eIF4G cleavage, but is in fact stimulated [31].
In order to test whether there was a causal relationship
between the speci¢c inhibition of viral protein synthesis and
eIF4G, the in£uence of the two caspase inhibitors on in vivo
eIF4GI cleavage was examined. HeLa cells were infected with
HRV2 in the presence of 200 WM zVAD.fmk or of 100 WM
zIETD.fmk. Western blot analysis of the protein extracts re-
vealed that by 8 h p.i. eIF4GI was completely cleaved in
control cells whereas in inhibitor-treated cells cleavage of
eIF4GI was completely blocked (Fig. 2B).
As 2Apro is responsible for eIF4G cleavage, the e¡ect of
zVAD.fmk and zIETD.fmk on in vitro eIF4GI cleavage in
HeLa cell extracts was tested using recombinant HRV2
2Apro. Indeed eIF4GI cleavage by HRV2 2Apro was already
inhibited by 15 WM zVAD.fmk and by 15 WM zIETD.fmk
(Fig. 2C). A similar degree of inhibition was observed for
CV B4 2Apro indicating that the e¡ect of caspase inhibitors
is not restricted to 2Apro of HRV2 (data not shown).
In order to increase stability and cell permeability,
zVAD.fmk and zIETD.fmk are generally applied as methyl
esters, i.e. as benzyloxycarbonyl-Val-Ala-Asp(OMe)-£uoro-
methyl ketone and as benzyloxycarbonyl-Ile-Glu(OMe)-Thr-
Asp(OMe)-£uoromethyl ketone, respectively [17,32]. After en-
tering the cell the methyl groups are removed by endogenous
esterases. However, the kinetics of the demethylation reac-
tions are not known. In order to examine the in£uence of
the presence of the methyl groups on the speci¢city, the in-
hibitory potential of zVAD.fmk (benzyloxycarbonyl-Val-Ala-
Asp(OMe)-£uoromethyl ketone) was compared with that of
the unmethylated form (benzyloxycarbonyl-Val-Ala-Asp-£uo-
romethyl ketone) in the in vitro eIF4GI cleavage reaction
using recombinant HRV2 2Apro. In contrast to the methylated
form of zVAD.fmk, the unmethylated form had no inhibitory
e¡ect on 2Apro cleavage of eIF4GI in vitro (Fig. 2C). This
suggests that under in vivo conditions the methylated form of
zVAD.fmk interacts with viral 2Apro which results in inhibi-
tion of virus multiplication. As zVAD.fmk becomes gradually
demethylated by cellular esterases, the inhibitor loses its a⁄n-
ity for 2Apro. As newly synthesized 2Apro is no longer inhib-
ited, viral synthesis is initiated and proceeds normally there-
after.
3.4. zVAD.fmk and zIETD.fmk delay 2Apro self-cleavage
The ¢rst step in the picornaviral polyprotein maturation is
catalyzed by 2Apro which cleaves between the C-terminus of
VP1 and its own N-terminus. We therefore checked the in£u-
ence of caspase inhibitors on self-processing of HRV2 2Apro
during translation in vitro in rabbit reticulocyte lysates. As
indicated in Fig. 3A, self-processing of 2Apro is clearly delayed
in the presence of 200 WM of the methylated form of
zVAD.fmk as compared to the control. 200 WM zIETD.fmk
exhibited a similar inhibitory in£uence on HRV2 2Apro activ-
ity as zVAD.fmk (data not shown). In contrast the unmethy-
lated form of zVAD.fmk did not impair cleavage at all.
3.5. Caspase inhibitors a¡ect activity of HRV2 2Apro as
determined with a synthetic substrate
In order to exclude potential e¡ects of endogenous cellular
proteinases which might be present in HeLa cell extracts, the
in vitro cleavage experiments were repeated using puri¢ed
recombinant 2Apro of HRV2 and the chromogenic peptide
TRPIITTA-pNA as substrate [19,24]. As shown in Fig. 3B,
again a strong inhibition by the methylated forms of
Fig. 2. A: In£uence of caspase inhibitors on synthesis of rhinovirus
structural proteins. HeLa cells were infected with HRV2 for 12 h in
the absence or in the presence of 200 WM zVAD.fmk or 100 WM
zIETD.fmk. The inhibitors were added at the time of infection and
4 h p.i. Autoradiogram of 12.5% SDS-PAGE showing synthesis of
35S-labeled proteins. (B) In vivo and (C) in vitro inhibition of eIF4-
GI cleavage by caspase inhibitors. B: HeLa cells were mock-infected
(lane 1) or were infected with HRV2 for 8 h in the absence (lane 2)
or in the presence of 200 WM zVAD.fmk (lane 3) or 100 WM
zIETD.fmk (lane 4). The inhibitors were added at the time of infec-
tion and 4 h p.i. C: HeLa cell protein extract (lane 1) was incuba-
ted at 30‡C for 4 h with HRV2 2Apro in the absence (lane 2) or in
the presence of 15 WM zIETD.fmk (lane 3), 15 WM of the methylat-
ed form of zVAD.fmk (lane 4) or 15 WM of the unmethylated form
of zVAD.fmk (lane 5). Samples were analyzed in 6% SDS^PAGE
and by Western blotting using polyclonal antibody against eIF4GI.
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zVAD.fmk and zIETD.fmk on 2Apro cleavage activity was
observed. The 50% inhibitory concentration values were de-
termined as 5.6U1036 mol/l for zVAD.fmk and 7.7U1036
mol/l for zIETD.fmk, respectively [25]. In contrast, the unme-
thylated form of zVAD.fmk did not inhibit the cleavage re-
action (Fig. 3B). Similar results were obtained for 2Apro of
CVB4 (data not shown).
4. Discussion
Cells infected with viruses frequently respond by induction
of apoptosis, which is characterized by activation of caspases.
In order to investigate whether there is an in£uence of apo-
ptotic events on HRV2 multiplication, the caspase inhibitors
zVAD.fmk and zIETD.fmk were employed. zVAD.fmk was
chosen since it is a general inhibitor of most caspases and
zIETD.fmk was employed as an inhibitor of high speci¢city
for caspase 8. Indeed it was observed that depending on the
time of addition of these inhibitors a reduction in virus yield
was obtained. Similar results were obtained with HRV14
(data not shown).
Fmk-derivatized peptides used as inhibitors of caspases are
usually employed as methyl esters. Inside the cell endogenous
esterases cause the demethylation of the inhibitors. As dem-
onstrated in this paper the methylated forms of the caspase
inhibitors show a signi¢cant inhibitory e¡ect on 2Apro both in
eIF4GI cleavage and in the self-cleavage assay. Apparently
the properties of the methylated peptide moieties of
zVAD.fmk and zIETD.fmk are not su⁄cient to confer exclu-
sive speci¢city for caspases. The cleavage speci¢city of 2Apro
of HRV2 has been investigated extensively [33]. The enzyme
tolerates a number of di¡erent amino acids in the P1 position
[13] including large side chains such as in Thr, Leu, Phe, Tyr
and Met and basic residues such as in Arg and Lys. However,
there is absolutely no cleavage of peptides harboring a neg-
atively charged residue such as Asp or Glu in P1, even when
all the other amino acids correspond to the viral polypeptide
cleavage site sequence [33]. As seen in the three-dimensional
structure, the site on the enzyme binding the P1 residue of the
inhibitor is fairly large but contains the carboxylate side chain
of Glu102 at the bottom of the pocket [3]. This negative
charge probably prevents the Asp side chain of the unmethy-
lated form of zVAD.fmk from entering the pocket due to
unfavorable electrostatic interactions. However, in the meth-
ylated form of zVAD.fmk the inhibitor can bind to 2Apro as
the additional methyl residue can be easily accommodated in
the binding pocket.
We therefore postulate that the transient nature of the in-
hibitory e¡ect on virus multiplication can be explained by the
gradual decrease in the concentration of methylated
zVAD.fmk. As addition of fresh zVAD.fmk results in e¡ective
inhibition of newly synthesized 2Apro, the antiviral e¡ect is
strongly enhanced upon repeated addition of the inhibitors.
Presently it is not clear whether zVAD.fmk and zIETD.fmk
block only 2Apro or whether both 2Apro and 3Cpro are inhib-
ited.
The inhibitory activity of zVAD.fmk and zIETD.fmk is
presumably not restricted to the HRV system. Indeed a tran-
sient inhibition of zVAD.fmk on CV B3 multiplication has
been observed recently [7]. Furthermore, an inhibition of the
release of CV B3 upon zVAD.fmk treatment was reported [8].
This was attributed to the inhibition of apoptosis by
zVAD.fmk as the titer of intracellular CV B3 was increased
while that of extracellular virus was decreased. In contrast, in
our experimental system total HRV2 yields were determined
comprising both intracellular and extracellular virus.
The results of this investigation are not only important for
the relationship between viral infection and apoptosis, they
are of more general signi¢cance. Considering the widespread
use of zVAD.fmk and similar fmk peptide derivatives in ap-
optosis research, it is important to consider that the methyl-
ated forms of the inhibitors may exhibit signi¢cant reactivity
towards ^SH-containing enzymes other than caspases.
Although speci¢city for caspases is increased upon demethy-
lation of the inhibitors, the kinetics of demethylation is un-
known and may vary between di¡erent cells and tissues. Thus,
inhibitory e¡ects caused by fmk-based peptide inhibitors do
not necessarily re£ect an involvement of caspases and can
therefore not be considered as proof of apoptosis.
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